The language of “regeneration” has become prominent in aesthetic medicine. Patients are increasingly asking about polynucleotides, platelet-rich plasma (PRP), platelet-rich fibrin (PRF) and collagen-stimulating injectables. These treatments do not all work in the same way, and they should not be grouped together as if they offer identical outcomes.
For practitioners, the opportunity is not simply to add fashionable procedures to a treatment menu. It is to understand the biology, product category, evidence, limitations and risks well enough to make a defensible clinical decision for each patient.
What does regenerative aesthetics mean?
Regenerative aesthetics is a broad, evolving term rather than a single regulated treatment class. It is generally used for interventions intended to support tissue quality or biological repair processes rather than only replace volume or temporarily alter muscle activity.
Examples include:
- Polynucleotides: injectable products containing purified nucleotide chains, promoted for effects on hydration, tissue quality and fibroblast activity.
- PRP: a preparation made from the patient’s own blood in which platelets are concentrated within plasma.
- PRF: another autologous platelet preparation, produced through a different processing approach and generally without anticoagulant.
- Biostimulatory injectables: products intended to encourage collagen production over time; their composition, licensed indications and risk profiles differ.
These distinctions matter. A practitioner must know exactly what is being administered, how it is prepared, where it is sourced, its regulatory status, the manufacturer’s instructions and whether the proposed use falls within the evidence and their own competence.
Evidence is developing — so claims must remain measured
Published research suggests potential benefits for some regenerative treatments, but the quality and consistency of evidence vary. A 2024 systematic review of polynucleotides identified encouraging findings while emphasising the need for larger studies and standardised protocols. An overview of systematic reviews on PRP for facial rejuvenation found that much of the underlying evidence was low or very low certainty, with variation in preparation methods, combination treatments and outcome measures.
This does not mean that every treatment lacks value. It means practitioners should avoid turning an emerging evidence base into a guarantee. Terms such as “reverses ageing”, “repairs DNA”, “permanent rejuvenation” or “clinically proven” require robust, treatment-specific substantiation and may mislead when used broadly.
Good consent describes realistic potential benefits, uncertainty, alternatives, recovery, costs, the likely treatment course and the possibility of little or no visible improvement.
Preparation is part of the treatment
Autologous procedures demand more than venepuncture and centrifugation. Safe PRP or PRF practice requires a controlled pathway from patient selection to disposal. That includes:
- checking relevant medical history, medication and contraindications;
- obtaining valid consent for blood collection and the aesthetic procedure;
- using suitable equipment and following a validated preparation protocol;
- maintaining asepsis throughout collection, processing and administration;
- ensuring identification and traceability of the patient’s sample;
- documenting device, consumable and batch details where applicable;
- recognising adverse reactions and knowing when to escalate.
Small changes in centrifugation, tube type, processing time and final concentration can alter the preparation. Practitioners should be able to explain their protocol, not simply repeat a brand’s marketing language.
Patient selection still comes first
The popularity of a treatment is not an indication for it. A structured consultation should identify the patient’s concern, assess skin and tissue, explore previous procedures, screen for contraindications and agree a proportionate plan.
Regenerative treatments may be unsuitable where there is active infection, uncontrolled inflammatory skin disease, relevant blood or clotting concerns, unrealistic expectations, or a need that would be better addressed by another clinical route. The specific product or procedure may introduce further contraindications.
Practitioners should also consider cumulative burden. A multi-session course is not “minimal” simply because each appointment is short. Patients need transparent information about the full programme, expected maintenance and total cost before deciding.
Complication readiness must match treatment ambition
Autologous does not mean risk-free, and “natural” is not a clinical safety category. Bruising, pain, swelling, infection, inflammatory reactions, vascular injury and unsatisfactory outcomes may occur depending on the procedure and site.
A practitioner should have clear aftercare, an emergency plan, access to appropriate support, and a documented referral pathway. They must recognise the limits of their role and escalate without delay when symptoms fall outside an expected recovery pattern.
Build capability, not just a treatment list
Regenerative aesthetics rewards disciplined learning. Strong practice brings together anatomy, consultation, infection prevention, venepuncture where relevant, product science, technique, evidence appraisal, complications management and reflective follow-up.
Training should include supervised practical assessment and meaningful feedback, not attendance alone. Practitioners should continue auditing outcomes, updating protocols and reviewing new evidence after qualification.
The responsible message for 2026 is clear: regenerative treatments may become an important part of modern aesthetic practice, but credibility will depend on restraint as much as innovation. Patients are best served by practitioners who can separate mechanism from marketing, explain uncertainty honestly and make safety the first measure of progress.
Related reading
Build regenerative practice on regulated foundations
Regenerative treatments sit on top of core clinical skills rather than beside them. Autologous procedures begin with safe venepuncture, and every injectable decision rests on anatomy, consent and complication readiness.
- Phlebotomy Training — supervised venepuncture practice for autologous procedures;
- CPD Level 5 Face Anatomy — the vascular knowledge behind safer injecting;
- CPD Level 5 Management of Dermal Fillers Complications — recognition, escalation and emergency planning;
- QUALIFI Level 7 Certificate in Aesthetic Practice — advanced, independently assessed clinical practice.
Explore all CFMSR courses or speak to the admissions team about the right starting level for your qualifications and experience.
This article is educational and does not replace product information, manufacturer instructions, professional regulation or supervised clinical training.